WNK1 belongs to a unique protein kinase family that lacks the catalytic lysine in its normal position. Mutations in human WNK1 and WNK4 have been implicated in causing a familial form of hypertension. Here we report that overexpression of WNK1 led to increased activity of cotransfected ERK5 in HEK293 cells. ERK5 activation was blocked by the MEK5 inhibitor U0126 and expression of a dominant-negative MEK5 mutant. Expression of dominantnegative mutants of MEKK2 and MEKK3 also blocked activation of ERK5 by WNK1.
Introduction
More than 500 protein kinases have been recognized in the human genome, approximately 1.7% of all human genes (1,2). These enzymes play crucial roles in regulating cellular processes and participate in most, if not all of the signal transduction pathways in cells.
Among them, WNKs (with no lysine [K]) are a newly described subfamily with a unique placement of the catalytic lysine responsible for binding to ATP (3) . WNKs exist in multicellular organisms including plants, C. elegans, Drosophila and mammals, but not in unicellular organisms such as S. cerevisiae (3) (4) (5) (6) (7) (8) . The well studied plant Arabidopsis thaliana has the largest number of WNK family members known with at least nine, some of which are implicated in controlling circadian rhythm (5, 6) . In contrast, both C. elegans and Drosophila have only one WNK in their genomes.
There are at least four mammalian WNK family members with high sequence identity within their catalytic domains (4, 8) . Rat WNK1, the first mammalian member of this protein kinase subfamily identified, contains an N-terminal kinase domain followed by an autoinhibitory domain and a long C-terminal tail (3, 9) . Disruption of the WNK1 gene in mice leads to embryonic lethality before E13(10). Lifton and colleagues showed that mutations in WNK1 and WNK1, on the other hand, was found to have no effect on NCC activity on its own. However, WNK1 relieved NCC inhibition by WNK4 (12) . These new findings provide a potential mechanism for regulation of blood pressure by WNKs and suggest an explanation for the finding that loss of WNK regulation causes hypertension.
MAP kinase (MAPK) cascades are involved in many signal transduction pathways including those regulating cell cycle, transcription, apoptosis and proliferation (13, 14) . A typical MAPK cascade consists of a MAPK kinase kinase (MAP3K or MEKK), and a MAPK kinase (MAP2K or MEK) which act in series on a MAPK. There are several MAPK pathways in mammals. One of them, the ERK5 MAPK pathway, contains MEK5 (MAP2K) and MEKK2/3 (MAP3K) as its upstream regulators (15) (16) (17) (18) (19) . ERK5 contains a long C-terminal tail, and its kinase domain most resembles ERK2. ERK5 can be activated by proliferative stimuli such as epidermal growth factor (EGF), serum, lysophosphatidic acid, neurotrophins and phorbol ester, as well as by stress stimuli such as sorbitol, H 2 O 2 , and UV irradiation (20) (21) (22) (23) (24) (25) (26) (27) (28) . The known ERK5 substrates include the MEF2 family members, MEF2A, C and D, and the ETS-like transcription factor SAP1a (21, 23) . The upstream kinase MEK5 contains two alternatively spliced forms α and β (16). MEK5 is the only known MAP2K in the ERK5 pathway (21) . Its sequence similarity to MEK1/2 renders it susceptible to the pharmacological inhibitors PD98059 and U0126, originally identified as selective blockers of MEK1/2 (21,29,30).
MEKK2 and MEKK3 are two closely related MAP3Ks with extremely high sequence identity within their catalytic domains, although less so within their N-terminal regulatory domains (31) . Both kinases have been shown to interact with MEK5 directly and activate the MEK5-ERK5 pathway (18, 19) . A dominant negative mutant of MEKK3 is capable of blocking by guest on http://www.jbc.org/
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Materials and Methods
Plasmids, subcloning, and mutagenesis
pCEP4-HA-ERK5 and pCEP4-HA-ERK2 were as described (3). pCMV5-Myc-WNK1
(1-491) and full length WNK1 were described previously (3, 9) . pCMV5-3xFlag vector was purchased from Sigma (St. Louis, MO). pCMV5-HA-MEKK2 and 3 were kindly provided by Dr. Gary Johnson (Univ. of Colorado, Denver, CO/Univ. North Carolina, Chapel Hill, NC) (31).
To make Flag-MEK5 α K195M and β K106M, Flag-MEKK2, and Flag-MEKK3 constructs, the ORFs were amplified by PCR and subcloned into pCMV5-3xFlag. To make constructs expressing GST fusions of MEKK2 and 3, cDNAs encoding residues 1-350 and 1-354 (N constructs), and 332-619 K385M and 350-626 K391M (C constructs) of MEKK2 and MEKK3, respectively, were amplified by PCR and subcloned into pGEX-KG. pCMV5-Myc-TAO2 (1-993) D169A was as described (32) . Site-directed mutagenesis was performed using the QuikChange kit (Stratagene) according to the manufacturer's directions.
Proteins and antibodies
GST-MEF2C (204-321) and His 6 -MEK6 K82M were as described (27, 33) . His 6 -WNK1 (198-491) was described previously (9) . Myelin basic protein (MBP) was purchased from Sigma. GST-MEKK2/3-N/C proteins were expressed using standard protocols. The anti-HA antibody (12CA5) was from Berkeley Antibody Company. The anti-Myc antibody (9E10) was from the National Cell Culture Center. The monoclonal anti-Flag antibody was obtained from Sigma. The polyclonal anti-WNK1 antibody Q256 and its preimmune serum were as described (3) . The anti-ERK1/2 antibody Y691 was described previously (34) . The anti-ERK5 antibody was purchased from Sigma. Cell culture, transfections, and harvesting HEK 293 cells were maintained, transfected, and harvested as described (35) . Lysis buffer with 1% Triton X-100 or NP-40 was used except for coimmunoprecipitation experiments, in which case detergent was omitted. Hela cells were grown in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS) and 1% L-glutamine at 37 o C under 10% CO 2 . For RNAi experiments, Hela cells were grown in 6-well plates to 30% confluence on the day of transfection. Cells were transfected with luciferase dsRNA as a control or WNK1 dsRNA oligonucleotides using Oligofectamine (Invitrogen) according to manufacturer's instructions.
After 72 h, cells were deprived of serum for 4 h before treatment.
Immunoblotting and immunoprecipitation
For immunoblotting, proteins from cell lysates were separated by SDS-PAGE followed 
Results
Overexpression of WNK1 activates ERK5 in HEK293 cells
We previously reported that overexpression of WNK1 (1-555) did not activate cotransfected MAPKs in HEK 293 cells (3). Subsequently, we identified an autoinhibitory domain in WNK1 located between residues 491 and 555 (9) . Because WNK1 (1-491) had much higher catalytic activity than WNK1 (1-555) in vitro, we thought it was necessary to examine the more active form, WNK1 (1-491), for its possible effects on the activities of MAPKs. Thus,
HA-tagged ERK2 or ERK5 was transfected into HEK293 cells along with either the vector or
Myc-tagged WNK1 (1-491). Remarkably, ERK5 activity assayed using its substrate GST-MEF2C was increased significantly by WNK1 (1-491) compared to the vector control (Fig. 1A ).
In contrast, ERK2 activity was not affected by WNK1 (1-491) when assayed with MBP ( 1D ). These results suggest that WNK1 might act as an upstream kinase in the ERK5 MAPK pathway.
Activation of ERK5 by WNK1 requires MEK5 activity
We next examined whether activation of ERK5 by WNK1 required the known MEK in the ERK5 pathway, MEK5. To address this question, we first used kinase-dead mutants (KM) of the two MEK5 isoforms, α and β. MEK5α K195M fully blocked activation of ERK5 by WNK1
( Fig. 2A) . Both ERK5 autophosphorylation and activity towards GST-MEF2C were reduced to the control value. Unexpectedly, MEK5β K106M had no effect in the same experiment. In addition, we utilized the pharmacological compound U0126 which specifically inhibits the activities of MEK1, MEK2 and MEK5, but not other MAP2Ks (30) . At 10 µM, U0126
efficiently blocked the activation of ERK5 by WNK1 in transfected cells treated for 1 h prior to harvest (Fig. 2B ). These findings indicate that MEK5 activity is crucial for activation of ERK5
by WNK1.
Activation of ERK5 by WNK1 is dependent on MEKK2 and MEKK3
MEKK2 and MEKK3, the two known MAP3Ks in the ERK5 MAPK pathway, interact with MEK5 and activate the MEK5-ERK5 cascade (18, 19) . To determine whether WNK1 acts upstream or downstream of MEKK2/3 in the ERK5 pathway, we examined the effects of dominant negative mutants of MEKK2/3 on ERK5 activation by WNK1. MEKK3 K391M prevented ERK5 activation by WNK1 (Fig. 3A) . Both ERK5 autophosphorylation and activity towards GST-MEF2C decreased to basal levels if the MEKK3 K391M mutant was coexpressed.
Similar results were also observed for MEKK2 K385M (Fig. 3B ). On the other hand, a kinase dead form of a MAP3K not known to be involved in the ERK5 pathway, TAO2 (1-993) D169A, did not affect the activation of ERK5 by WNK1 (Fig. 3B) . Likewise, kinase dead mutants of the MAP4K PAK1 and the MAP3K MEKK1also failed to block ERK5 activation by WNK1 (data not shown). These data suggest that WNK1 most likely acts upstream of MEKK2 and MEKK3
in the ERK5 pathway.
Endogenous WNK1 coimmunoprecipitates with MEKK2 and MEKK3
Because dominant negative mutants of MEKK2 and MEKK3 could block ERK5
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activation by WNK1, we tested whether WNK1 and MEKK2/3 might exist in a complex in cells.
HEK293 cells were transfected with Myc-tagged WNK1 (1-491) and HA-tagged MEKK3.
WNK1 was immunoprecipitated with anti-Myc and the precipitates were blotted with anti-HA.
HA-MEKK3 was readily detected in the precipitates from lysates containing both WNK1 and MEKK3, but not from those containing only MEKK3 (Fig. 4A ). The converse also revealed an association; MEKK3 was immunoprecipitated with anti-HA and the precipitates were blotted with anti-Myc. Again, Myc-WNK1 was only detected in the precipitates from lysates containing both MEKK3 and WNK1, and not from those containing only WNK1 ( (Fig. 4C) . The catalytic activities of MEKK2/3 were not required because the kinase dead mutants also coimmunoprecipitated with WNK1 (Fig. 4C ).
Next we wanted to examine whether the endogenous WNK1 could coimmunoprecipitate with MEKK2/3. HEK293 cells were transfected with Flag-tagged MEKK2 or MEKK3.
Endogenous WNK1 was immunoprecipitated from the cell lysates with the Q256 antibody and precipitates were blotted with anti-Flag. As a control, the preimmune serum of Q256 was also used for immunoprecipitation. As shown in Fig. 4D , WNK1 immunoprecipitates contained significant amounts of MEKK2/3. Neither the preimmune serum nor a control antibody Y691
(anti-ERK1/2) pulled down comparable amounts of MEKK2. These results support the conclusion that MEKK2/3 and WNK1 are associated in cells.
WNK1 phosphorylates the N-terminus of MEKK2 and MEKK3 in vitro
Because WNK1 lies upstream of MEKK2/3 and they can exist in a complex in cells, we reasoned that MEKK2 and MEKK3 might be direct substrates of WNK1. To test this possibility, we used Flag-tagged MEKK2/3 (KM) proteins immunoprecipitated from 293 cells as in vitro substrates for His-WNK1 (198-491). As shown in Fig. 5A , both MEKK2 and MEKK3 were phosphorylated by WNK1. We also expressed GST fusion proteins of MEKK2 and MEKK3 in bacteria to test as WNK1 substrates. N-terminal and C-terminal (KM) fragments of the two MAP3Ks were expressed, and in both cases, the N-terminal fragment, but not the C-terminal fragment was phosphorylated by recombinant WNK1 (Fig. 5B ) and also by endogenous WNK1
immunoprecipitated from cells treated with NaCl (Fig. 5C ). These results are consistent with the idea that WNK1 is a MAP4K in the ERK5 pathway. However, the phosphorylation of MEKK2/3 by WNK1 does not appear to directly alter their catalytic activities because preincubation of MEKK2/3 with WNK1 in the presence of ATP neither increased nor decreased their kinase activities (data not shown).
Overexpression of WNK1 activates cotransfected MEKK3 in HEK293 cells
To test whether WNK1 could affect the activity of MEKK3 in cells, we transfected 293 cells with either vector control or Myc-tagged WNK1 (1-491) along with Flag-tagged MEKK3.
MEKK3 was immunoprecipitated from cell lysates and assayed using His 6 -MEK6 K82M as the substrate. Overexpression of WNK1 (1-491) increased the autophosphorylation of MEKK3 as well as its activity towards His 6 -MEK6 K82M (Fig. 5D) , showing that coexpression with WNK1 in cells stimulates MEKK3 activity. Interestingly, this activation is independent of the catalytic activity of WNK1, because a kinase defective mutant of WNK1 also activated cotransfected MEKK3 to a similar extent (data not shown). 
WNK1 is required for activation of ERK5 by EGF in Hela cells
We have presented evidence that overexpression of WNK1 is sufficient to activate the ERK5 MAPK pathway. However, whether WNK1 is required for ERK5 activation under any physiological circumstances is still unknown. Growth factors such as EGF and stress stimuli are well documented activators of ERK5. Therefore, we tested whether WNK1 is required for ERK5 activation by EGF using RNAi to knock down expression of endogenous WNK1 in Hela cells. ERK5 activation by many agents including EGF leads to a decrease in its electrophoretic motility on gels (Fig. 6A) , providing a simple assessment of its activity. We successfully reduced expression of endogenous WNK1 as shown in Fig. 6B . ERK5 activation by 1 ng/ml of EGF was partially reduced by suppression of WNK1 expression, suggesting that WNK1 is required for ERK5 activation by EGF under these circumstances. With higher concentrations of EGF, the requirement for WNK1 became less pronounced (data not shown).
Discussion
Since it was first cloned and characterized three years ago, the atypical protein kinase WNK1 has attracted considerable interest primarily because it has been linked to the regulation of blood pressure (3, 8) . Although progress was made in the last two years in defining how WNK1 is regulated and in suggesting an effect of WNK1 on ion channels, the biochemical pathways regulated by WNK1 remain unknown. Here we provide evidence that WNK1 can activate the MAPK ERK5 through MEKK2/3.
The following observations suggest that WNK1 is a MAP4K in the ERK5 pathway: 1) Interestingly, our data suggest a role for only one of two isoforms of MEK5 in activation of ERK5 by WNK1. MEK5α has an additional 89 residues at its N-terminus compared to MEK5β due to alternative splicing, while MEK5β appears to be more widely expressed (16) .
The inactive form of MEK5α was a very effective inhibitor, while the comparable mutant of MEK5β was not. A recent study has suggested that wild type MEK5β can act as a dominant negative to block ERK5 activation by EGF or by a constitutively active form of MEK5α (36).
The mechanisms underlying this discrepancy are not known.
Significantly, we have demonstrated that WNK1 is required for ERK5 activation by EGF. We also found a partial requirement for WNK1 in the activation of ERK5 by H 2 O 2 (data not shown). In contrast, WNK1 was not required for activation of ERK5 by either sorbitol or NaCl (data not shown). Surprisingly, there is a poor correlation of the requirement for WNK1 in ERK5 activation by these agents and the sensitivity of WNK1 itself to be activated by them.
NaCl and sorbitol are significantly stronger WNK1 activators than H 2 O 2 , and we have thus far failed to reveal activation of WNK1 by EGF. Thus, the potential involvement of WNK1 in a pathway may not be obvious based on changes in its kinase activity alone. These results indicate that WNK1 participates in ERK5 activation by a subset of physiological ERK5 regulators.
There are four WNK homologs in mammals that share a high degree of identity within their kinase domains, but significantly lower identity outside the kinase domains (4, 8) . A recent study suggests that WNK1 and WNK4 might have opposite effects on channel regulation (12).
Thus, it will be important to determine whether any of the other WNK family members also activate ERK5. Currently, we are testing WNK2 and WNK4 for their effects on the ERK5
pathway.
In summary, we demonstrated in this study that WNK1 activates the ERK5 MAPK pathway through MEKK2/3. The identification of potential WNK1 substrates other than myelin basic protein provides a starting point to map biochemical pathways that WNK1 regulates.
Future studies should shed more light on the important roles WNK1 plays in various cellular processes including ion transport. 
